Outset Medical, Inc. (OM) Covered Calls

Outset Medical, Inc. is a medical technology pioneer dedicated to reducing the cost and complexity of dialysis. The company’s flagship Tablo Hemodialysis System is a first-of-its-kind enterprise solution that integrates water purification and dialysate production into a single, compact console. By enabling dialysis across the continuum of care—from the hospital to the home—Outset empowers patients and providers with greater flexibility and improved clinical outcomes.

You can sell covered calls on Outset Medical, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for OM (prices last updated Tue 4:16 PM ET):

Outset Medical, Inc. (OM) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
3.34 -0.01 3.31 3.50 200K - 0.1
Covered Calls For Outset Medical, Inc. (OM)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 2.5 0.05 3.45 -27.5% -401.5%
Apr 17 2.5 0.05 3.45 -27.5% -189.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Outset Medical, Inc. (OM) is transforming the multibillion-dollar kidney care market with its Tablo Hemodialysis System. Unlike traditional dialysis setups that require expensive infrastructure and specialized water rooms, Tablo is a "dialysis clinic on wheels." It combines high-fidelity sensors, automated water purification, and on-demand dialysate production into one integrated system. This allows healthcare facilities to "insource" their dialysis programs, reducing operational costs and improving treatment consistency while offering patients a simpler, more intuitive path to home-based care.

In early 2026, the company reached a major strategic milestone by receiving FDA 510(k) clearance for its next-generation Tablo platform. This updated system is the first in the industry to meet the FDA’s most rigorous cybersecurity standards established in mid-2025. By February 2026, Outset has successfully expanded its footprint to over 1,000 care sites across the United States. The company is currently scaling production of its Tablo Cartridge consumables, which drive a high-margin recurring revenue model. Despite navigating a challenging macroeconomic environment for small-cap MedTech, Outset enters 2026 with a refocused sales strategy and a growing pipeline of enterprise-wide contracts with major health systems and national dialysis providers.

Competitive Landscape

The competitive landscape for Outset Medical includes global healthcare conglomerates and specialized medical equipment firms. Primary rivals that are publicly traded on the NASDAQ or NYSE and offer active options markets include Baxter International Inc. and Fresenius Medical Care AG. Baxter and Fresenius are the traditional titans of the dialysis space, providing both clinic-based services and a wide array of home-dialysis hardware.

Other notable competitors in the medical device and specialty diagnostics sectors with active options trading include Medtronic plc and Accuray Incorporated. Outset distinguishes itself through its "tech-first" approach; while legacy competitors often rely on siloed hardware components, Tablo’s cloud-connected data analytics platform provides real-time treatment monitoring and seamless EMR integration. This software-enabled moat allows Outset to compete on efficiency and total cost of ownership rather than just hardware price, a critical advantage as providers shift toward value-based care models.

Strategic Outlook

Strategic innovation is currently focused on the Q2 2026 commercial launch of the Next-Gen Tablo, featuring enhanced hardware durability for high-acuity environments and a modernized operating system. By early 2026, the company has prioritized improving service margins through AI-driven predictive maintenance, which identifies potential component failures before they cause treatment interruptions. These initiatives are designed to shorten the time between planned maintenance intervals and further reduce the "cost-per-treatment" for acute care customers.

The long-term outlook involves the expansion of the Tablo ecosystem into international markets and the development of biometric-linked diagnostics to personalize treatment parameters. Management is prioritizing a path to cash-flow breakeven by optimizing its manufacturing supply chain and expanding its "Direct-to-Patient" home training modules. By leveraging its lead in medical device cybersecurity and its unique "enterprise solution" positioning, Outset aims to become the standard of care for decentralized kidney therapy, ensuring it remains a resilient disruptor in the evolving global healthcare landscape.